Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin

Anesthesia and Analgesia

Volumn 90, Issue 2, 2000, Pages 292-298

  Koster, Andreas ^a   Kuppe, Herrmann ^a   Crystal, George J ^b   Mertzlufft, Fritz ^c  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b UNIVERSITY OF ILLINOIS   (United States)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CASE REPORT; DRUG SAFETY; FEMALE; HUMAN; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0033966055     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200002000-00010     Document Type: Article

References (36)

1. Greinacher A. Heparin-induzierte Thrombozytopenien. Internist 1996;37:1172-8.
2. Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73:1592-6.
3. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992;22:145-52.
4. Slaughter TF, Greenberg CS. Heparin-associated thrombocytopenia and thrombosis: implications for perioperative management. Anesthesiology 1997;87:667-75.
5. Shorten GD, Communale ME. Heparin-induced thrombocytopenia. J Cardiothorac Vase Anesth 1996;10:521-30.
6. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characteriza-tion of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51.
7. Hach-Wunderle V, Kainer K, Salzmann G, et al. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg 1997;173:117-9.
8. Salmenperä MT, Levy JH. Pharmacologic manipulation of hemostasis - anticoagulation. In: Lake CL, Moore RA, eds. Blood. 1st ed. New York: Raven Press, 1995;105-17.
9. Vun CM, Evans S, Chong BH. Cross-reactivity study of low-molecular-weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 1996;81:525-32.
10. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemost 1998;80:292-7.
11. Blakeman B. Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Semin Hematol 1999; 36(Suppl 1):37-41.
12. Walls JT, Curtis JJ, Silver D, et al. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990;108:686-93.
13. Bauer TL, Arepaly G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95: 1242-6.
14. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractioned heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 1996;128:376-83.
15. Greinacher A, Amiral J, Drummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-5.
16. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options. Postgrad Med 1998;103:169-71.
17. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25(Suppl 1):43-9.
18. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
19. Koster A, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998; 89:777-80.
20. Look KA, Sahud M, Flaherty S, Zehnder JL. Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombo-cytopenia-thrombosis. Am J Clin Pathol 1997;108:78-82.
21. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999;36(Suppl 1):22-8.
22. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101502-7.
23. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197-202.
24. Pötzsch B, Hund S, Madlener K, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin dotting time. Thromb Haemost 1997;77:920-5.
25. Riess FC, Pötzsch B, Bleese N, et al. Rekombinantes Hirudin als Antikoagulanz für den kardiopulmonalen Bypass in der Herzchirurgie: Klinische Erfahrungen. Z Herz-, Thorax-Gefässchirurgie 1997;11:79-87.
26. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-93.
27. Koster A, Kuppe H, Mertzlufft F. Cardiopulmonary bypass with recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a synopsis of 19 cases. Br J Anaesth 1999; 82(Suppl 1):35(A.116).
28. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
29. Nowack G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997;109:354-8.
30. Vetter HO, Kaulbach HG, Schmitz C, et al. Experience with the Novacor left ventricular assist system as a bridge to cardiac transplantation, including the new wearable system. J Thorac Cardiovasc Surg 1995;109:74-80.
31. O-Yurvati AH, Laub GW, Southgate TJ, et al. Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 1994;57: 1565-8.
32. Matsuo T, Koide M, Kario K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin Thromb Hemost 1997;23:517-22.
33. Harenberg J, Huhle G, Piazolo L, et al. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997;23:189-96.
34. Novacek G, Kapiotis S, Jilma B, et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb Res 1997;88:283-90.
35. Lamriben L, Tiberghien F, Delacour JL, et al. Value of orgaran in hemodialysis during heparin-induced thrombopenia [letter]. Presse Med 1996;25:1303.
36. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-5.